After BioNTech SE and Pfizer, Moderna and NIH, 3rd mRNA Covid vaccine player CureVac now partners with fellow German company Bayer Pharmaceuticals, to accelerate clinical, regulatory and supply. Increased collaboration across the industry will be another major positive impact of Covid-19 crisis. #postcovid19 #vaccinessavelives #innovation #launches Continue reading

Oxford University/AstraZeneca Covid-19 vaccine, based on viral vector technology and now approved by UK authorities, will be vital for developing countries. Compared to mRNA based vaccines, it is cheaper to make and can be stored at standard refrigeration temperature, making it easier to use in poorer and harder-to-reach parts of the world. Fantastic achievement ! #postcovid19 #innovation #launch #vaccinessavelives Continue reading

Behind the success of BioNTech Pfizer and Moderna mRNA-based Covid vaccines, lays the story of 4 immigrants, Katalin Kariko, Ugur Sahin, Özlem Türeci and Albert Bourla, facing doubts and rejection through patience and hard work. Kudos to you all ! #postcovid19 #vaccinessavelives Continue reading

Following Pfizer-BioNTech 90% efficacy announcement, Moderna data show 94% efficacy against Covid-19, while allowing easier storage: long term at -20°C, up to 30 days at 2°C-8°C. #postcovid19 #vaccinessavelives #mrna #launch Continue reading

mRNA treatments are about to revolutionize treatments of infectious and cancer diseases. After Covid-19 vaccines, next step will be hyper-selective cancer vaccines, with innovative companies such as BioNTech, Moderna, CureVac or Kernal Biologics. #postcovid19 #biotech #vaccinessavelives #immunooncology Continue reading

With growing anti-vax sentiment, and regardless of the political agenda, it is critical that the industry and regulatory authorities take all necessary time and steps before approving Covid19 vaccines. #postcovid19 #vaccinessavelives Continue reading